

Isabelle Bedrosian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594999/publications.pdf>

Version: 2024-02-01

112
papers

4,389
citations

109321

35
h-index

114465

63
g-index

115
all docs

115
docs citations

115
times ranked

4680
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclin E and Survival in Patients with Breast Cancer. <i>New England Journal of Medicine</i> , 2002, 347, 1566-1575.	27.0	522
2	Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. <i>Cancer</i> , 2003, 98, 468-473.	4.1	334
3	Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2010, 102, 401-409.	6.3	192
4	Incidence of Sentinel Node Metastasis in Patients With Thin Primary Melanoma (#1 mm) With Vertical Growth Phase. <i>Annals of Surgical Oncology</i> , 2000, 7, 262-267.	1.5	173
5	Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. <i>Cancer</i> , 2000, 88, 2540-2545.	4.1	172
6	Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. <i>Cancer</i> , 1999, 85, 1098-1103.	4.1	160
7	Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy. <i>Cancer Prevention Research</i> , 2010, 3, 1026-1034.	1.5	138
8	Impact of Clinicopathological Factors on Sensitivity of Axillary Ultrasonography in the Detection of Axillary Nodal Metastases in Patients With Breast Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 1025-1030.	1.5	120
9	Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. <i>Annals of Surgical Oncology</i> , 2016, 23, 3190-3198.	1.5	119
10	Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 749-756.	1.5	108
11	Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 56-63.	1.7	107
12	Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. <i>JAMA Surgery</i> , 2015, 150, 778.	4.3	94
13	Selective use of sentinel lymph node surgery during prophylactic mastectomy. <i>Cancer</i> , 2006, 107, 1440-1447.	4.1	79
14	High incidence of germline <i>BRCA</i> mutation in patients with ER low ⁺ /PR low ⁺ /HER2 ⁻ negative tumors. <i>Cancer</i> , 2015, 121, 3422-3427.	4.1	78
15	A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. <i>Cancer</i> , 2010, 116, 2543-2548.	4.1	66
16	Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions. <i>Annals of Surgical Oncology</i> , 2002, 9, 457-461.	1.5	63
17	Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?. <i>Annals of Surgical Oncology</i> , 2015, 22, 4270-4279.	1.5	62
18	Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. <i>American Journal of Surgery</i> , 2006, 192, 552-555.	1.8	61

#	ARTICLE	IF	CITATIONS
19	Cyclin E deregulation alters the biologic properties of ovarian cancer cells. <i>Oncogene</i> , 2004, 23, 2648-2657.	5.9	58
20	Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. <i>Cancer</i> , 2009, 115, 962-971.	4.1	56
21	Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. <i>Annals of Surgery</i> , 2016, 263, 178-183.	4.2	56
22	Outcome After Curative Resection for Locally Recurrent Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 175-182.	1.3	55
23	Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. <i>Annals of Surgical Oncology</i> , 2017, 24, 2925-2934.	1.5	54
24	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. <i>PLoS ONE</i> , 2015, 10, e0136851.	2.5	54
25	Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. <i>Cancer</i> , 2012, 118, 5637-5643.	4.1	52
26	Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. <i>Annals of Surgical Oncology</i> , 2009, 16, 1606-1611.	1.5	50
27	Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 19645-19660.	1.8	49
28	Active Macromolecule Uptake by Lymph Node Antigen-Presenting Cells: A Novel Mechanism in Determining Sentinel Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2000, 7, 98-105.	1.5	48
29	Contralateral prophylactic mastectomy: current perspectives. <i>International Journal of Women's Health</i> , 2016, 8, 213.	2.6	47
30	Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia. <i>Annals of Surgical Oncology</i> , 2017, 24, 70-76.	1.5	45
31	Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. <i>Breast Cancer Research</i> , 2012, 14, R82.	5.0	44
32	Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 652-659.	1.5	41
33	Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 795-802.	0.8	39
34	Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1548.	7.1	39
35	Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2630-2638.	1.6	38
36	Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes. <i>Journal of Cancer</i> , 2020, 11, 1341-1350.	2.5	38

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1119-1127.	1.6	36
38	Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2015, 22, 3208-3212.	1.5	36
39	Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. <i>PLoS ONE</i> , 2015, 10, e0127678.	2.5	34
40	Cyclin E deregulation is an early event in the development of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 651-659.	2.5	32
41	DCIS and axillary nodal evaluation: compliance with national guidelines. <i>BMC Surgery</i> , 2017, 17, 12.	1.3	32
42	The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 150.	5.0	29
43	^{99m} Tc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. <i>Journal of Nuclear Medicine</i> , 1999, 40, 1143-8.	5.0	28
44	Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. <i>Cancer</i> , 2007, 110, 2542-2550.	4.1	25
45	Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. <i>Cancer Medicine</i> , 2018, 7, 2718-2726.	2.8	25
46	Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. <i>Breast Journal</i> , 2018, 24, 28-34.	1.0	23
47	Practical Implications of the Publication of Consensus Guidelines by the American Society for Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 338-348.	0.8	21
48	Mammographic breast density is associated with the development of contralateral breast cancer. <i>Cancer</i> , 2017, 123, 1935-1940.	4.1	21
49	Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. <i>Clinical Breast Cancer</i> , 2018, 18, 276-281.	2.4	21
50	Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2 ⁻) breast cancer before chemo-endocrine therapy. <i>Annals of Oncology</i> , 2021, 32, 642-651.	1.2	21
51	Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 4277-4283.	1.5	21
52	Evolution in practice patterns of axillary management following mastectomy in patients with ≥ 2 positive sentinel nodes. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 435-444.	2.5	20
53	Surgeon perception versus reality: Opioid use after breast cancer surgery. <i>Journal of Surgical Oncology</i> , 2019, 119, 909-915.	1.7	20
54	Survey of the Deficits in Surgeons' Knowledge of Contralateral Prophylactic Mastectomy. <i>JAMA Surgery</i> , 2016, 151, 391.	4.3	19

#	ARTICLE	IF	CITATIONS
55	Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 91-99.	1.5	18
56	Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions. <i>Annals of Surgery Open</i> , 2020, 1, e008.	1.4	18
57	Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. <i>American Journal of Surgery</i> , 2009, 198, 387-391.	1.8	17
58	Cyclin Eâ€“Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 4800-4806.	7.0	15
59	Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. <i>Advances in Radiation Oncology</i> , 2017, 2, 291-300.	1.2	15
60	Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. <i>Cancer</i> , 1999, 85, 1098-1103.	4.1	14
61	Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. <i>Practical Radiation Oncology</i> , 2019, 9, e4-e13.	2.1	13
62	Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. <i>Annals of Surgical Oncology</i> , 2020, 27, 4613-4621.	1.5	13
63	Integrative Analyses of Multilevel Omics Reveal Preneoplastic Breast to Possess a Molecular Landscape That is Globally Shared with Invasive Basal-Like Breast Cancer. <i>Cancers</i> , 2020, 12, 722.	3.7	13
64	Imaging in Locoregional Management of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2351-2361.	1.6	13
65	Suppression of Akt-mTOR Pathway-A Novel Component of Oncogene Induced DNA Damage Response Barrier in Breast Tumorigenesis. <i>PLoS ONE</i> , 2014, 9, e97076.	2.5	12
66	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 615-623.	2.5	12
67	Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use. <i>Annals of Surgical Oncology</i> , 2020, 27, 730-735.	1.5	12
68	Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. <i>Nature Communications</i> , 2020, 11, 5156.	12.8	12
69	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4603-4612.	1.5	12
70	Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 403-415.	2.5	12
71	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. <i>Cancer</i> , 2017, 123, 2618-2625.	4.1	11
72	Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. <i>Annals of Surgical Oncology</i> , 2018, 25, 2932-2938.	1.5	11

#	ARTICLE	IF	CITATIONS
73	OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 815-820.	1.5	10
74	Surgical clinical trials in melanoma. <i>Surgical Clinics of North America</i> , 2003, 83, 385-403.	1.5	9
75	Contralateral Prophylactic Mastectomy: Anxiety, Knowledge and Shared Decision Making. <i>Annals of Surgical Oncology</i> , 2015, 22, 3767-3768.	1.5	9
76	Trends in Regional Nodal Management of Breast Cancer Patients with Low Nodal Burden. <i>Annals of Surgical Oncology</i> , 2019, 26, 4346-4354.	1.5	9
77	Debating the Optimal Approach to Nodal Management After Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 42-48.	3.8	9
78	HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 95-104.	2.5	8
79	Subareolar and Peritumoral Injection Identify Similar Sentinel Nodes for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2002, 9, 169-176.	1.5	8
80	Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). <i>Breast Cancer Research</i> , 2016, 18, 93.	5.0	7
81	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 8610-8621.	1.5	7
82	Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. <i>Journal of Surgical Oncology</i> , 2021, 124, 989-994.	1.7	7
83	Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. <i>Npj Breast Cancer</i> , 2021, 7, 87.	5.2	7
84	Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 363-374.	2.5	6
85	Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 437-444.	0.8	6
86	Evaluation of Sensitivity to Endocrine Therapy Index (SET _{2,3}) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). <i>Clinical Cancer Research</i> , 2022, 28, 3287-3295.	7.0	6
87	A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 23-29.	1.5	5
88	Optimizing Patient Positioning to Reduce Variation in the Measurement of Breast Cancer-Related Lymphedema. <i>Lymphatic Research and Biology</i> , 2019, 17, 440-446.	1.1	5
89	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020, 27, 359-366.	1.5	5
90	Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2020, 66, 934-945.	3.2	5

#	ARTICLE	IF	CITATIONS
91	Magnetic Resonance Imaging-Guided Biopsy of Mammographically and Clinically Occult Breast Lesions. <i>Annals of Surgical Oncology</i> , 2002, 9, 457-461.	1.5	5
92	Contralateral Prophylactic Mastectomy and Survival: An Ongoing Challenge. <i>Annals of Surgical Oncology</i> , 2014, 21, 3372-3374.	1.5	4
93	Helping Patients Understand and Cope with BRCA Mutations. <i>Current Oncology Reports</i> , 2022, 24, 733-740.	4.0	4
94	Response: Re: Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1372-1373.	6.3	3
95	How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 281-288.	1.1	3
96	Screening Mammography: Getting to Version 2.0. <i>Annals of Surgical Oncology</i> , 2018, 25, 2500-2501.	1.5	3
97	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. <i>Breast Journal</i> , 2019, 25, 575-577.	1.0	3
98	Who should get a contralateral prophylactic mastectomy for breast cancer?. <i>Cancer</i> , 2019, 125, 1400-1403.	4.1	3
99	The paradox of breast MRI: does finding occult disease make a difference?. <i>Bulletin of the American College of Surgeons</i> , 2012, 97, 57-9.	0.3	3
100	Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer. <i>BMC Cancer</i> , 2022, 22, 282.	2.6	3
101	Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer: A National Cancer Database analysis. <i>Cancer</i> , 2021, 127, 2196-2203.	4.1	2
102	ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 458-459.	1.5	2
103	Impact of Breast Cancer Subtypes on Local-Regional Outcomes. <i>Current Breast Cancer Reports</i> , 2010, 2, 107-113.	1.0	1
104	Surveillance of women with a personal history of breast cancer by tumour subtype. <i>Clinical Radiology</i> , 2017, 72, 266.e1-266.e6.	1.1	1
105	Prophylactic Mastectomy and Breast Reconstruction in Patients at High Risk for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 13-20.	1.0	1
106	Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	1
107	Current Multidisciplinary Management of High-Risk Breast Lesions. <i>Current Breast Cancer Reports</i> , 2015, 7, 81-89.	1.0	0
108	Breast conserving therapy or mastectomy: a done deal or one worth returning to?. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 187-189.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis. <i>Translational Behavioral Medicine</i> , 2020, 10, 347-354.	2.4	0
110	ASO Author Reflections: Performance of Contralateral Risk-Reducing Mastectomy in Multigene Panel-Tested Patients is High in All Types of Germline Mutation Carriers. <i>Annals of Surgical Oncology</i> , 2020, 27, 678-679.	1.5	0
111	Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 622-622.	1.6	0
112	Sentinel Lymph Node Surgery During Prophylactic Mastectomy (Methodology)., 2008, , 543-556.		0